Myllia Biotechnology

Myllia Biotechnology combines CRISPR screening with single-cell RNA sequencing (CROP-Seq), leveraging two transformative technologies to enable genetic screening for complex cellular phenotypes. We utilize the CRISPR screening workflow to map the impact of thousands of genetic perturbations on the global transcriptome, thus effectively establishing a paradigm for next generation CRISPR screens. In collaboration with biotech/pharma companies across the globe, we perform high-throughput customized CRISPR screens on a fee-for-service basis to support early-stage drug target discovery.

Our CRISPR screens can be performed in cancer cells and primary T cells using CRISPR KO, CRISPR interference or CRISPR activation coupled to various read-outs including fitness, FACS and single-cell transcriptomics. Myllia's platform has broad applications in identifying novel drug targets, disease-associated gene functions, and understanding genetic variants linked to disease risk.

www.myllia.com